Literature DB >> 18691651

Functional genomics of cancer.

Edison T Liu1.   

Abstract

Cancer genomics has focused on the discovery of genetic mutations and chromosomal structural rearrangements that either increase susceptibility to cancer or support the cancer phenotype. Though each individual mutation may induce specific cancer phenotypes, it is the interaction of the functional changes in transcription and proteins that give the characteristics of cancer. Whereas molecular biology focuses on the impact of individual genes on the cancer state, functional genomics assesses the comprehensive genetic alterations in a cancer cell and seeks to integrate the dynamic changes in these networks so that cancer phenotypes can be explained. Most commonly, the transcriptome is the target of analysis because of the maturity, completeness, and speed of the technologies, but progressively the proteome is being studied in the same comprehensive manner. The focus of this review, however, will be on the functional consequences of cancer genomic alterations with special reference to the transcriptome and in the perturbed gene expression found in cancer states. The developments in the past two years (which is our time horizon) have been heavily driven by the applications of the new ultra high-throughput sequencing approaches assisted by computational discovery strategies. The precision and comprehensiveness of the analyses are astonishing. The collective results, when taken together, suggest that despite the large range of mutational and epigenetic events, there is a convergence onto a finite number of pathways that drive cancer behavior. Moreover, the interconnectivity of regulatory control mechanisms suggest that the earlier concepts distinguishing driver from passenger abnormalities may undervalue the contribution of the numerous aberrations that have small but additive effects on cancer virulence.

Entities:  

Mesh:

Year:  2008        PMID: 18691651     DOI: 10.1016/j.gde.2008.07.014

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  12 in total

Review 1.  Binding of pro-prion to filamin A: by design or an unfortunate blunder.

Authors:  C Li; W Xin; M-S Sy
Journal:  Oncogene       Date:  2010-08-09       Impact factor: 9.867

2.  Identification of novel driver tumor suppressors through functional interrogation of putative passenger mutations in colorectal cancer.

Authors:  Lu Zhang; Kakajan Komurov; Woodring E Wright; Jerry W Shay
Journal:  Int J Cancer       Date:  2012-07-21       Impact factor: 7.396

3.  The DNA methylation landscape of human melanoma.

Authors:  Seung-Gi Jin; Wenying Xiong; Xiwei Wu; Lu Yang; Gerd P Pfeifer
Journal:  Genomics       Date:  2015-09-15       Impact factor: 5.736

4.  RET/PTC rearrangements arising from a small population of papillary thyroid carcinoma cells, possible candidate for passenger mutation.

Authors:  Tadao Nakazawa; Shin-ichi Murata; Tetsuo Kondo; Dongfeng Niu; Kunio Mochizuki; Tomonori Kawasaki; Tetsu Yamane; Nobuki Nakamura; Ryohei Katoh
Journal:  Virchows Arch       Date:  2009-06-03       Impact factor: 4.064

5.  Using large-scale molecular data sets to improve breast cancer treatment.

Authors:  Chad J Creighton
Journal:  Breast Cancer Manag       Date:  2012-05-01

Review 6.  New tools for functional genomic analysis.

Authors:  Xin Chen; Eric Jorgenson; Siu Tim Cheung
Journal:  Drug Discov Today       Date:  2009-05-27       Impact factor: 7.851

7.  Cord Blood-Derived Quiescent CD34+ Cells Are More Transcriptionally Matched to AML Blasts Than Cytokine-Induced Normal Human Hematopoietic CD34+ Cells.

Authors:  Richard L Darley; Alex Tonks; Chinmay Munje; Robert K Hills; Anthony Whetton; Alan K Burnett
Journal:  Gene Expr       Date:  2015

8.  Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine.

Authors:  Joanna D Holbrook; Joel S Parker; Kathleen T Gallagher; Wendy S Halsey; Ashley M Hughes; Victor J Weigman; Peter F Lebowitz; Rakesh Kumar
Journal:  J Transl Med       Date:  2011-07-25       Impact factor: 5.531

9.  Trial watch: Peptide vaccines in cancer therapy.

Authors:  Erika Vacchelli; Isabelle Martins; Alexander Eggermont; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2012-12-01       Impact factor: 8.110

10.  SOX4 transcriptionally regulates multiple SEMA3/plexin family members and promotes tumor growth in pancreatic cancer.

Authors:  Hsin-Yi Huang; Yu-Yao Cheng; Wei-Chih Liao; Yu-Wen Tien; Chih-Hsin James Yang; Su-Ming Hsu; Pei-Hsin Huang
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.